Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

W tym Artykule

  • Podsumowanie
  • Streszczenie
  • Wprowadzenie
  • Protokół
  • Wyniki
  • Dyskusje
  • Ujawnienia
  • Podziękowania
  • Materiały
  • Odniesienia
  • Przedruki i uprawnienia

Podsumowanie

A detailed protocol is provided here for establishing human breast organoids from patient-derived breast tumor resections or normal breast tissue. The protocol provides comprehensive step-by-step instructions for culturing, freezing, and thawing human patient-derived breast organoids.

Streszczenie

Breast cancer is a complex disease that has been classified into several different histological and molecular subtypes. Patient-derived breast tumor organoids developed in our laboratory consist of a mix of multiple tumor-derived cell populations, and thus represent a better approximation of tumor cell diversity and milieu than the established 2D cancer cell lines. Organoids serve as an ideal in vitro model, allowing for cell-extracellular matrix interactions, known to play an important role in cell-cell interactions and cancer progression. Patient-derived organoids also have advantages over mouse models as they are of human origin. Furthermore, they have been shown to recapitulate the genomic, transcriptomic as well as metabolic heterogeneity of patient tumors; thus, they are capable of representing tumor complexity as well as patient diversity. As a result, they are poised to provide more accurate insights into target discovery and validation and drug sensitivity assays. In this protocol, we provide a detailed demonstration of how patient-derived breast organoids are established from resected breast tumors (cancer organoids) or reductive mammoplasty-derived breast tissue (normal organoids). This is followed by a comprehensive account of 3D organoid culture, expansion, passaging, freezing, as well as thawing of patient-derived breast organoid cultures.

Wprowadzenie

Breast cancer (BC) is the most commonly occurring malignancy in females, with 287,850 new cases estimated to be diagnosed in the United States in 20221. Despite the recent advances in early detection with annual screenings, targeted therapies, and a better understanding of genetic predisposition, it prevails to be the second leading cause of cancer deaths in females in the United States, with >40,000 deaths attributed to breast cancer annually1. Breast cancer is currently classified into multiple subtypes based on histopathological and molecular evaluation of the primary tumor. Better subtype stratification has impro....

Protokół

Tumor resections from breast cancer patients, along with the distal and adjacent normal tissue, were obtained from Northwell Health in accordance with Institutional Review Board protocols IRB-03-012 and IRB 20-0150, and with written informed consent from the patients.

NOTE: All procedures mentioned below were performed in a mammalian tissue culture BSL2 room designated for patient samples upon approval of the biosafety committee. All procedures should be performed following safety protocols maintaining aseptic conditions in biosafety cabinets. Each centrifugation step is performed at room temperature (RT) unless stated otherwise. Tissue/org....

Wyniki

We have established a biobank of patient-derived breast tumor organoids comprising various subtypes11. Additionally, we have established multiple normal breast organoid lines derived from reductive mammoplasty tissue samples or adjacent/distal normal breast from BC patients using the approach outlined in Figure 1.

The various patient-derived breast tumor organoid lines differ in their morphology (Figure 2) and .......

Dyskusje

Our lab has successfully employed the above protocols to establish organoids from naïve tumor resections or scrapings. We have also utilized this protocol to develop normal organoids from breast tissue obtained via reductive mammoplasties or from cancer patients' adjacent or distal normal breast tissue. About 30%-40% of the resected primary tumors resulted in successful long-term (>passage 8) tumor organoid cultures. The tumor organoid lines that tapered off after a few passages either had an outgro.......

Ujawnienia

The authors declare no conflicts of interest.

Podziękowania

We would like to thank members of the Spector lab for critical discussions throughout the course of this work. We thank Norman Sachs and Hans Clevers (Hubrecht Institute, Netherlands) for initially providing us with their organoid culturing protocol. We acknowledge the CSHL Cancer Center Histology and Microscopy Shared Resources for services and technical expertise (NCI 2P3OCA45508). We thank Dr. Qing Gao for assistance with histological sample preparation. We are grateful for the support of Dr. Karen Kostroff (Northwell Health) for providing patient tumor samples. We also appreciate the efforts of the Northwell Health Biobanking team for sample acquisition, and we th....

Materiały

NameCompanyCatalog NumberComments
15 mL conical tubesVWR525-1068
175 cm2 tissue culture flaskVWR (Corning)29185-308
37 °C bead bath
37 °C CO2 incubator
50 mL conical tubesVWR525-1077
50 mL vacuum filtration system (0.22 µm Filter)Millipore SigmaSCGP00525SCGP00525
500 mL Rapid-Flow Filter Unit, 0.2 µm aPES membrane, 75 mm diameterNalgene566-0020
6-well culture plates Greiner Cellstar82050-842
75 cm2 tissue culture flaskVWR (Corning)29185-304
96-well opaque platesCorning353296For CTG assay
A83-01Tocris2939
Advanced DMEM/F12Gibco12634-010
B-27 supplementLife Technologies12587010
BioTek Synergy H4 Hybrid Microplate ReaderFisher Scientific (Agilent)For dual luciferase assay and CTG assay
BSA fraction V (7.5%)Thermo Fisher15260037
Cell Titer-Glo (CTG) ReagentPromegaG9683luminescent cell viability assay
Centrifuge Eppendorf5804
Collagenase from Clostridium histolyticumMillipore SigmaC5138Type IV
CryolabelsAmazonDTCR-1000Direct Thermal Cryo-Tags, White, 1.05 x 0.5"
Cryovials Simport Scientific Inc.T311-1
Countess 3 Automated Cell CounterThermo FisherAMQAX2000
DMEM, high glucose, pyruvateThermo Fisher (Gibco)11995040
Dual Luciferase Reporter Assay SystemPromegaE1910
Dulbecco’s Phosphate Buffered Saline (1X)Gibco14190-144DPBS
Epidermal growth factor (hEGF)PeprotechAF-100-15
Fetal Bovine Serum (FBS)Corning35-010-CV
FGF-10 (human)Peprotech100-26
FGF-7/KGF (human)Peprotech100-19
GlutaMaxLife Technologies35050061
HEK293T cellsATCCCRL-3216 For TOPFlash Assay
HEK293T-HA-Rspondin1-Fc cellsR&D Systems3710-001-01Cultrex HA-R-Spondin1-Fc 293T Cells
HEPESLife Technologies15630-080
Heregulinβ-1 (human)Peprotech100-03
Matrigel Growth Factor Reduced (GFR) Basement Membrane MatrixCorning356231Phenol-red free, LDEV-free; basement membrane matrix
Mr. Frosty Cell Freezing ContainerThermo Fisher5100-0001
Mycoplasma detection kitLonzaLT07-418
N-acetyl-l-cysteineMillipore SigmaA9165
Nalgene Rapid-Flow Sterile Disposable Filter Units with PES MembranesThermo Fisher166-0045 
NicotinamideMillipore SigmaN0636
Noggin (human)Peprotech120-10C
P1000, P200, P10 pipettes with tips
p38 MAPK inhibitor (p38i) SB 202190Millipore SigmaS7067
Parafilmtransparent film
Penicillin-StreptomycinLife Technologies15140122
Plasmid1: pRL-SV40PAddgene27163
Plasmid2: M51 Super 8x FOPFlashAddgene12457
Plasmid3: M50 Super 8x TOPFlashAddgene12456
pluriStrainer 200 µmpluriSelect43-50200-01
PrimocinInvivogenANT-PM-1
Recovery Cell Culture Freezing MediumThermo Fisher (Gibco)12648-010cell freezing medium
Red Blood Cell lysis bufferMillipore Sigma11814389001
R-spondin conditioned mediaIn-house or commercial from Peprotech120-38
Scalpel (No.10)Sklar InstrumentsJun-10
Shaker (Incu-shaker Mini)BenchmarkH1001-M
TGF-β receptor inhibitor A 83-01Tocris2939
Trypan Blue Stain (0.4%)Gibco15250-061
TrypLE Express Enzyme (1X), phenol redLife Technologies12605028cell dissociation reagent
X-tremeGENE 9 DNA transfection reagentMillipore Sigma6365779001
Y-27632 Dihydrochloride (RhoKi)Abmole BioscienceY-27632
ZeocinThermo FisherR25001

Odniesienia

  1. Siegel, R. L., Miller, K. D., Fuchs, H. E., Jemal, A. Cancer statistics, 2022. CA: A Cancer Journal for Clinicians. 72 (1), 7-33 (2022).
  2. Greenwalt, I., Zaza, N., Das, S., Li, B. D. Precision Medicine and Targeted Therapies in Breast Cancer.

Przedruki i uprawnienia

Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE

Zapytaj o uprawnienia

Przeglądaj więcej artyków

Patient derived OrganoidsBreast Tumor Organoids3D In Vitro ModelCellular HeterogeneityTissue DissociationCollagenase IVRed Blood Cell LysisBasement Membrane MatrixAdDF Medium

This article has been published

Video Coming Soon

JoVE Logo

Prywatność

Warunki Korzystania

Zasady

Badania

Edukacja

O JoVE

Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone